Gooderham, M.; Spelman, L.; Imafuku, S.; Romanelli, M.; Merola, J. F.; Armstrong, A. W.; Colston, E.; Banerjee, S.; Scharnitz, T.; Blauvelt, A. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2023, 7, s219.